Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume32
Issue numbersuppl abstr e15607
Publication statusPublished - 2014

Cite this